1. Home
  2. PRAA vs NMRA Comparison

PRAA vs NMRA Comparison

Compare PRAA & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PRA Group Inc.

PRAA

PRA Group Inc.

HOLD

Current Price

$15.63

Market Cap

639.1M

Sector

Finance

ML Signal

HOLD

NMRA

Neumora Therapeutics Inc.

HOLD

Current Price

$1.69

Market Cap

554.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAA
NMRA
Founded
1996
2019
Country
United States
United States
Employees
170
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
639.1M
554.0M
IPO Year
2002
2023

Fundamental Metrics

Financial Performance
Metric
PRAA
NMRA
Price
$15.63
$1.69
Analyst Decision
Buy
Buy
Analyst Count
3
8
Target Price
$24.50
$7.50
AVG Volume (30 Days)
577.0K
1.2M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.23
EPS
0.73
N/A
Revenue
$1,201,837,000.00
N/A
Revenue This Year
$2.01
N/A
Revenue Next Year
$2.53
N/A
P/E Ratio
$20.60
N/A
Revenue Growth
7.83
N/A
52 Week Low
$10.25
$0.72
52 Week High
$22.55
$3.65

Technical Indicators

Market Signals
Indicator
PRAA
NMRA
Relative Strength Index (RSI) 44.31 36.05
Support Level $15.04 $1.46
Resistance Level $15.76 $1.99
Average True Range (ATR) 0.71 0.12
MACD 0.12 0.00
Stochastic Oscillator 89.50 3.12

Price Performance

Historical Comparison
PRAA
NMRA

About PRAA PRA Group Inc.

PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: